Key Highlights

● Intensity Therapeutics resumed dosing in its INVINCIBLE-4 breast-cancer trial on July 15, 2026, after a redesigned, single-injection protocol addressed skin-irritation issues, while the small biotech reported just $10.2 million in cash and more than 20 partnering conversations for lead drug INT230-6.

● As of March 31, 2026, Intensity reported $10.2 million in cash, down from $11.9 million at December 31, 2025, with first-quarter 2026 R&D expense of $1.2 million.

● The clinical data come from very small, unblinded cohorts of 7 to 14 patients per arm subject to statistical noise, and the trial was already paused once for a safety signal.

● Investors should watch for enrollment and interim data from the restarted INVINCIBLE-4 trial.

Intensity Therapeutics, a clinical-stage oncology company trading on Nasdaq under the ticker INTS, restarted patient dosing on July 15, 2026, in its Phase 2 INVINCIBLE-4 trial testing INT230-6 in triple-negative breast cancer. The restart follows a nine-month enrollment pause triggered by skin irritation in treated patients and a subsequent protocol change approved by Swiss regulators. The news arrives alongside early efficacy data the company has touted as favorable, a July 1 mid-year update describing more than 20 partnering discussions for INT230-6, and a company that, after a 1-for-25 reverse split earlier this year, carries a market cap of roughly $12 million and just $10.2 million in cash. Encouraging but early clinical signals set against a thin balance sheet define the debate around this micro-cap name.

What happened

On July 15, 2026, Intensity Therapeutics announced it had resumed dosing INT230-6 in INVINCIBLE-4, its randomized, open-label Phase 2 trial evaluating the intratumoral drug candidate as presurgical treatment for triple-negative breast cancer (TNBC), alongside standard-of-care chemotherapy and immunotherapy. Enrollment had been paused in September 2025 after some patients developed skin irritation. In response, the company amended its protocol with Swissmedic and the Swiss ethics committee, reducing the drug-to-tumor volume ratio and switching from multiple injections to a single injection per tumor. Regulators approved the change on March 26, 2026, and dosing resumed in Switzerland in mid-July, with expansion planned to France. The company expects to enroll roughly 47 more patients toward a total of 61.

Why the development matters

The restart removes an overhang that had stalled INVINCIBLE-4 for roughly nine months. Small preliminary datasets, 5 of 7 patients (71.4%) achieving pathological complete response on INT230-6 plus standard-of-care, versus 2 of 6 (33%) on standard-of-care alone, plus a reported 44% reduction in grade 3-or-higher adverse events, are the kind of early signal that can support partnering conversations, but the cohorts are too small (14 patients total through the data cutoff) to be statistically robust or predictive of a larger trial's outcome. The disclosed partnering interest is notable for a company this size, but no partnership, licensing deal, or term sheet has been announced, and management has not specified deal economics, structure, or timing.

Company and product background

Intensity Therapeutics is developing INT230-6, an intratumoral injection combining cisplatin and vinblastine sulfate with a proprietary amphiphilic diffusion-enhancing molecule the company calls SHAO, designed to make the drugs soluble in both fat and water so they spread evenly through a solid tumor after direct injection, triggering localized cell death and, the company says, releasing tumor antigens that can activate an immune response without broad systemic immunosuppression. Its two later-stage programs are INVINCIBLE-4 (Phase 2, presurgical TNBC, primary endpoint pathological complete response, tested against a standard-of-care immunochemotherapy regimen) and INVINCIBLE-3 (Phase 3, second/third-line metastatic soft-tissue sarcoma, INT230-6 monotherapy versus standard of care, primary endpoint overall survival, 21 patients enrolled before its March 2025 pause). Management has said more than 200 patients have been dosed across completed INT230-6 studies and has cited a peer-reviewed publication in eBioMedicine supporting the drug's efficacy and immune-engagement mechanism. Neither late-stage program has reported registration-enabling data, and INT230-6 has no FDA approval in any indication.

Financial position

As of March 31, 2026, Intensity reported $10.2 million in cash, down from $11.9 million at December 31, 2025. First-quarter 2026 R&D expense was $1.2 million (down from $2.2 million a year earlier) and G&A expense was $1.3 million, producing a net loss of $2.4 million for the quarter, versus $3.3 million a year prior. For full-year 2025, the company reported a net loss of $11.6 million (versus $16.3 million in 2024), with R&D expense of $6.8 million and G&A expense of $5.2 million, and said it raised more than $20 million in gross proceeds during 2025 through two public offerings, a registered direct offering, and ATM issuances. In its March 27, 2026 year-end release, management said the cash raised extended its operating runway "into the second quarter of 2027", guidance as of that date, not reaffirmed in the subsequent Q1 2026 release. The company established a new $60 million ATM facility in March 2026, largely undrawn as of the last balance sheet reviewed, and completed a 1-for-25 reverse split (effective February 18, 2026) to regain Nasdaq's $1.00 minimum bid-price compliance, resolved March 6, 2026. No debt was disclosed.

Bull case

Proponents point to a differentiated intratumoral mechanism with published disease-control and survival data from earlier studies, a resumed and redesigned Phase 2 breast-cancer trial with a safety-focused protocol change, preliminary pathological complete response rates that compare favorably to the standard-of-care arm in a small cohort, and reported inbound partnering interest from more than 20 counterparties at a major industry conference, potential precursors to a licensing deal that could bring non-dilutive capital.

Risk case

The clinical data come from very small, unblinded cohorts (7-to-14 patients per arm) subject to statistical noise, and the trial was already paused once for a safety signal. INVINCIBLE-3 remains funding-constrained. No partnership has been signed despite months of disclosed discussions. Cash of $10.2 million against continuing losses points to near-term reliance on the ATM facility or additional dilutive financing, and the stock already underwent a 96% share-count reduction via reverse split earlier in 2026 to maintain its Nasdaq listing, reflecting prior share-price weakness.

What investors should watch next

Investors should track: enrollment and interim data from the restarted INVINCIBLE-4 trial in Switzerland and France; the planned third-quarter 2026 resumption of INVINCIBLE-3 sarcoma enrollment at U.S. sites; any signed partnership for INT230-6; usage of the $60 million ATM facility and its dilutive impact; and the next quarterly filing for updated cash and burn-rate figures.

Conclusion

Intensity Therapeutics has cleared an operational hurdle by resuming its breast-cancer trial with a modified, safety-conscious protocol, and it has disclosed encouraging, if very preliminary, efficacy signals alongside notable partnering interest. Yet the company remains a pre-revenue, thinly capitalized biotech with unconfirmed partnership terms, small-sample clinical data, and a cash position that likely requires financing within the coming year. Investors should weigh the genuine scientific and partnering interest against the statistical limitations of the data and the company's dependence on further capital raises.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.